Locus licenses CRISPR tech to Janssen in potential $818m deal
US-based Locus Biosciences has announced it will license its CRISPR-Cas3 technology to Janssen, a subsidiary of American pharmaceutical company Johnson & Johnson, in a deal worth a potential $818 million.
Pierce Bainbridge adds two partners to NY office
Los Angeles-based law firm Pierce Bainbridge Beck Price & Hecht has hired two partners to its New York office.
UK publishes further no-deal Brexit guidance for medicines
The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
Indian Supreme Court reinstates Monsanto GM cotton seed patent
The Supreme Court of India has ruled that biotechnology company Monsanto’s patent for genetically modified cotton seeds is valid and enforceable in the country.
Eli Lilly to purchase Loxo Oncology for $8bn
American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.
India removes cap from patented rare disease drugs
India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Teva settles Sensipar patent dispute with Amgen
Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Bristol-Myers Squibb to acquire Celgene in $74bn deal
American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Canadian companies complete handover of drugs rights
Nuvo Pharmaceuticals has acquired the rights covering more than 20 drugs from fellow Canadian company Aralez Pharmaceuticals.
Court invalidates Illumina patents in Ariosa row
Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.
